Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 24Burkitt Lymphoma 19Lymphoma, Follicular 14Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 6Recurrence 5Prostatic Neoplasms, Castration-Resistant 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoproliferative Disorders 3Lymphoma, T-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Prostate Cancer Metastatic 2Plasmablastic Lymphoma 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

Rituximab 13Cyclophosphamide 9Magnetic Resonance Spectroscopy 7Lenalidomide 7venetoclax 6obinutuzumab 5ibrutinib 5Specimen Handling 5fludarabine phosphate 4fludarabine 4Whole-Body Irradiation 4Prednisone 4CT-P10 4Biopsy 4zanubrutinib 3orelabrutinib 3Vincristine 3Mycophenolic Acid 3Cyclosporine 3polatuzumab vedotin 2pirtobrutinib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Doxorubicin 2Busulfan 2Bendamustine Hydrochloride 2voruciclib 1treosulfan 1tafasitamab 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × Prednisone × 90 days × Clear all
NCT04542824 2026-06-02

EPCOREâ„¢ NHL-3

Genmab

Phase 1/2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT07609446 2026-05-27

Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma

The First Affiliated Hospital of Soochow University

Not yet recruiting
30 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04433156 2026-04-09

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Henan Cancer Hospital

Phase 2 Completed
26 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡